Argos Therapeutics Inc., of Durham, N.C., said it validated the durability of the immune response for metastatic renal cell carcinoma patients treated with AGS-003
Argos Therapeutics Inc., of Durham, N.C., reported updated results from its Phase II study of AGS-003, its most advanced product candidate for the treatment of metastatic renal cell carcinoma (mRCC
Argos Therapeutics Inc., of Durham, N.C., said the first patients were enrolled in the ADAPT Phase III study testing the ability of AGS-003, a personalized dendritic cell-based immunotherapy, in combination with standard targeted therapy to extend overall survival vs
Argos Therapeutics Inc., of Durham, N.C., said its ongoing Phase III ADAPT study testing personalized immunotherapy candidate AGS-003 in Stage IV kidney cancer was reviewed during the International Kidney Cancer Symposium in Chicago
Argos Therapeutics Inc., of Durham, N.C., said it secured a special protocol assessment for a Phase III study of AGS-003 in metastatic renal cell carcinoma
Argos Therapeutics Inc., of Durham, N.C., presented positive Phase Ia data for AGS-009, a monoclonal antibody-based lupus therapy, at the European League Against Rheumatism Congress in Berlin
Argos Therapeutics Inc., of Durham, N.C., said study results published in the Journal of Medical Virology demonstrated that analytical treatment interruption to assess the antiviral activity of its Arcelis personalized immunotherapy for HIV is an acceptable strategy for at least 16 weeks
Argos Therapeutics Inc., of Durham, N.C., reported updated results from its Phase II study of AGS-003, an Arcelis immunotherapy, in combination with Sutent (sunitinib, Pfizer Inc.), showing that treatment prolonged survival in patients with unfavorable-risk metastatic renal cell carcinoma
Argos Therapeutics Inc., of Durham, N.C., presented a high resolution immune monitoring analysis of Phase II study AGS-003-006, testing Arcelis immunotherapy AGS-003 in combination with Sutent (sunitinib, Pfizer Inc.) in patients with advanced renal cell carcinoma (RCC), with results showing a statistically significant correlation between antitumor memory T-cell responses and overall survival
Argos Therapeutics, of Durham, N.C., announced that its Arcelis immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes in a Phase II combination study in newly diagnosed, metastatic RCC patients with unfavorable prognosis
Argos Therapeutics, of Durham, N.C., announced that interleukin (IL)-12 secretion can predict the potency of the company's Arcelis dendritic cell (DC) immunotherapy and can be used as a potency marker in a Phase III trial testing its lead product, AGS-003, in metastatic renal cell carcinoma
Argos Therapeutics Inc., of Durham, N.C., initiated a double-blind, placebo-controlled, dose-escalation, Phase Ia trial of AGS-009 for systemic lupus erythematosus
Argos Therapeutics Inc., of Durham, N.C., said data from a Phase IIa trial of ARS-004, its Arcelis HIV program, demonstrated a significant reduction in viral load and a delay in viral rebound kinetics during a 12-week antiretroviral treatment interruption when compared to pre-ART viral loads
Argos Therapeutics Inc., of Durham, N.C., reported interim Phase II data showing that AGS-003 plus Sutent (sunitinib, Pfizer Inc.) resulted in median progression-free survival of 14.9 months for intermediate risk and six months for poor risk renal cell carcinoma patients
Argos Therapeutics Inc., of Durham, N.C., said Phase II data with AGS-004 showed that the personalized immunotherapy has a positive impact on the genetic diversity of residual HIV virus, and also results in substantially increased time to viral rebound in HIV patients treated with AGS-004 following antiretroviral therapy interruption
Argos Therapeutics Inc., of Durham, N.C., presented data from the Phase IIa trial of AGS-004, providing information on rebound viral genetic diversity in HIV patients treated with the personalized immunotherapy following antiretroviral therapy interruption
Argos Therapeutics, of Durham, N.C., announced positive data from a Phase II trial that evaluated the safety, clinical response and immune response of AGS-003 in newly diagnosed patients with metastatic renal cell carcinoma
Argos Therapeutics Inc., of Durham, N.C., has begun a Phase IIa trial of its AGS-003 therapy, in combination with sunitinib, for the treatment of newly diagnosed advanced renal cell carcinoma
Argos Therapeutics Inc., of Durham, N.C., disclosed the publication of findings on its RNA amplification process